Acumen Pharmaceuticals and Lonza join forces to drive innovation in Alzheimer's treatment
Thursday, 4 April 2024, 13:01
Acumen Pharmaceuticals Collaborates with Lonza
Acumen Pharmaceuticals has teamed up with Lonza to manufacture sabirnetug, an innovative antibody targeted at toxic AβOs in Alzheimer's treatment, utilizing Lonza's extensive resources.
Key Highlights:
- Collaboration: Partnership between Acumen Pharmaceuticals and Lonza
- Sabirnetug: Antibody aimed at toxic AβOs in Alzheimer's
- Innovation: Leveraging Lonza's manufacturing expertise
This collaboration signifies a crucial advancement in the pursuit of effective treatments for Alzheimer's disease, highlighting the importance of strategic partnerships in driving medical innovation forward.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.